ROBERT BRAUER: Open Payments
NPI 1063401412 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$522 in 21 payments from 9 companies in 2025. Trend: 2023 $928 · 2024 $1,461 · 2025 $522
Food & beverage: $413Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $162 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
| ABBVIE INC. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $16 |
Products named: HETLIOZ, VRAYLAR, AUSTEDO XR, CAPLYTA, INGREZZA, COBENFY, REXULTI, ARISTADA.
Industry payments across OH — which companies pay providers there.
